1600023N17Rik Inhibitors
Chemical inhibitors of 1600023N17Rik utilize various mechanisms to disrupt its functional activity by targeting different components of the signaling pathways that lead to its activation. Wortmannin and LY294002 are compounds that inhibit phosphoinositide 3-kinases (PI3K), a class of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking, which are integral to the activation of the Akt signaling pathway. By inhibiting PI3K, these chemicals prevent the phosphorylation and subsequent activation of Akt, thereby reducing the activation of downstream proteins like 1600023N17Rik. Wortmannin achieves this through an irreversible mechanism, while LY294002 binds reversibly, but both ultimately lead to a decrease in 1600023N17Rik activity by hindering the PI3K/Akt pathway.
In addition to PI3K inhibitors, MK-2206 acts specifically to inhibit Akt by allosterically binding to its pleckstrin homology (PH) domain, resulting in dephosphorylation and inactivation. This inactivation of Akt by MK-2206 directly decreases the phosphorylation-dependent activation of downstream targets such as 1600023N17Rik. Another compound, Rapamycin, disrupts the mTOR pathway, which is downstream of Akt and is crucial for cell growth and metabolism. By forming a complex with FKBP12 and inhibiting mTOR, Rapamycin cuts off the downstream signaling that would contribute to the functional activity of 1600023N17Rik. Furthermore, Dasatinib, although known for its broad specificity as a tyrosine kinase inhibitor, can attenuate the PI3K/Akt pathway signaling by inhibiting upstream kinases, which in turn reduces the functional activity of 1600023N17Rik. Lastly, SB203580 and SP600125, which inhibit p38 MAP kinase and c-Jun N-terminal kinase (JNK) respectively, can also influence the PI3K/Akt pathway. By inhibiting these kinases, the compounds may indirectly affect the functional activity of 1600023N17Rik, as the PI3K/Akt pathway can be modulated by MAP kinase pathway activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal metabolite of fungi that acts as a potent and irreversible inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, Wortmannin prevents the phosphorylation and activation of Akt, a kinase downstream of PI3K. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic molecule that functions as a specific inhibitor of PI3K. Similar to Wortmannin, LY294002 inhibits PI3K activity, leading to a reduction in Akt kinase activation. The functional inhibition of 1600023N17Rik by LY294002 is achieved by limiting the phosphorylation signals that would typically be mediated through the PI3K/Akt pathway, which is known to regulate a variety of downstream proteins, including 1600023N17Rik. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is a highly selective inhibitor of Akt. This allosteric inhibitor binds to the pleckstrin homology (PH) domain of Akt, leading to its dephosphorylation and inactivation. By directly inhibiting Akt, MK-2206 would reduce the kinase activity necessary for the phosphorylation and subsequent activation of downstream proteins. Therefore, the functional inhibition of 1600023N17Rik is the result of suppressed Akt signaling, which would otherwise contribute to the activation of this protein. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a macrolide compound that inhibits mTOR (mechanistic target of rapamycin) by forming a complex with FKBP12. The mTOR pathway is a key regulator of cell growth and metabolism, and it acts downstream of Akt. The inhibition of mTOR by Rapamycin would impair the signaling required for the activity of several proteins downstream of mTOR, including 1600023N17Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole compound that selectively inhibits p38 MAP kinase. The p38 MAP kinase pathway is known to interact with the PI3K/Akt pathway. Inhibition of p38 MAP kinase by SB203580 can lead to a decrease in the functional activity of proteins that are regulated by the PI3K/Akt pathway, such as 1600023N17Rik. Therefore, the inhibition of 1600023N17Rik is indirectly achieved through the suppression of p38 MAP kinase activity, which influences the PI3K/Akt signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK). JNK is part of the MAP kinase pathway and can regulate the activity of various proteins through its signaling cascade. By inhibiting JNK, SP600125 can indirectly inhibit the functional activity of proteins that are affected by JNK signaling, including those potentially regulated by the PI3K/Akt pathway like 1600023N17Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that selectively inhibits MEK1/2,It seems there might be a misunderstanding. Your message includes a table template but does not specify what information you would like to include or what instructions you have for me. If you can provide context or clarify your request, I would be happy to assist you with generating or filling out the table with appropriate information. | ||||||